Phoenix Pharmacologics, Inc.

Lexington, KY 40506

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $1.74MM
First Award Date 08/20/99
Most Recent Award Date 02/04/05

Key Personnel

Last Name Name Awards Contact
Clark Mike A Clark 4
Bomalaski John S Bomalaski 3

7 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/04/05 - 01/31/06

DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemic administration of unformulated huTNFalpha has been tested in humans. All studies indicated the dose limiting toxicity was usually hypotension, th...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/11/04 - 01/31/05

DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemic administration of unformulated huTNFalpha has been tested in humans. All studies indicated the dose limiting toxicity was usually hypotension, th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/02 - 12/31/02

Hyperuricemia (elevated serum uric acid) results in gouty arthritis and chronic renal disease. Severe hyperuricemia can occur following cancer chemotherapy (tumor lysis syndrome) and organ transplantation (most common in heart and kidney transplant patients) which may result in acute uric acid nephropathy with resultant metabolic disorders and d...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/02 - 03/31/03

DESCRIPTION: The distinctive arginine requirement of hepatocellular carcinomas and malignant melanomas provides the basis for a new potential chemotherapy. Just as acute lymphocytic leukemia cells require asparagine and E. coli asparaginase enzyme can be used to effect a cure for this disease, we propose using a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/04/01 - 02/03/02

DESCRIPTION (PROVIDED BY APPLICANT): The long-term goal of the proposed research is the development of effective anti-cancer agents, modified human tumor necrosis factor-alphas (hTNFas). TNFa is a potent anti-neoplastic agent but its therapeutic application has been limited by its significant side effects...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/01 - 03/31/02

DESCRIPTION: The distinctive arginine requirement of hepatocellular carcinomas and malignant melanomas provides the basis for a new potential chemotherapy. Just as acute lymphocytic leukemia cells require asparagine and E. coli asparaginase enzyme can be used to effect a cure for this disease, we propose using a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/20/99 - 05/31/00

The distinctive arginine requirement of hepatocellular carcinomas, malignant melanomas and some sarcomas provides the basis for a new potential chemotherapy. The enzyme arginine deiminase (ADI) can deplete serum arginine; moreover, the duration of this depletion is significantly extended by covalent attachment of polyethylene glycol (PEG) to ADI...